Figure 3From: Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancerTumor efficacy. Best percent change in target lesion sum from screening compared to day 35 or any day later during study treatment, each column is representing 1 patient [A]. Progression free survival (days), each column is representing 1 patient [B].Back to article page